ESC Professional Premium Access

Lipids - Drug therapy 1

Event: ESC Congress 2022
Topic: Drug therapy
Session type: Moderated ePosters
Date: 26 August 2022
Time: 14:15 - 15:00

Congress Session

6 presentations in this session

Correlation of lipoprotein (a) with parameters of lipid profile and other cardiovascular risk factors in patients with familial combined hyperlipidemia

Speaker: Doctor I. Andrikou (Athens, GR)
Thumbnail

Cost-effectiveness of cholesterol-lowering drugs for secondary cardiovascular prevention in the UK: ezetimibe, evolocumab, and alirocumab

Speaker: Doctor T. Michaeli (Mannheim, DE)
Speaker: Mr D. Michaeli (Mannheim, DE)
Thumbnail

Recurrent atherosclerotic cardiovascular disease events preventable with guideline recommended lipid-lowering treatment following myocardial infarction

Speaker: Doctor R. Rosenson (New York, US)
Thumbnail

Simulation of bempedoic acid in the lipid-lowering treatment pathway using the European contemporary SANTORINI cohort of high- and very high-risk patients

Speaker: Doctor A. Bilitou (Munich, DE)
Thumbnail

PCSK9 inhibitors: effectiveness of treatment and changes in background lipid-lowering therapy in a real world Italian population. The AT-TARGET-IT study

Speaker: Doctor C. Basile (Naples, IT)
Thumbnail

Worldwide comparative efficacy of nutraceuticals on lipid profile. an updated systematic review and network meta-analysis

Speaker: Doctor T. Osadnik (Zabrze, PL)
Thumbnail

7 speakers from this session

Doctor Ioannis Andrikou

Hippokration General Hospital, Athens (Greece)
1 presentation
0 follower

Doctor Thomas Michaeli

, Mannheim (Germany)
1 presentation
0 follower

Mr Daniel Tobias Michaeli

University Medical Centre of Mannheim, Mannheim (Germany)
1 presentation
0 follower

Doctor Robert Rosenson

Icahn School of Medicine at Mount Sinai, New York (United States of America)
2 presentations
0 follower

Doctor Aikaterini Bilitou

Daiichi Sankyo Europe, Munich (Germany)
0 follower

Doctor Christian Basile

Federico II University Hospital, Naples (Italy)
1 presentation
0 follower

Doctor Tadeusz Osadnik

The Medical University of Silesia, Zabrze (Poland)
0 follower

This platform is supported by

logo Novo Nordisk